Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8963349 | PMC |
| http://dx.doi.org/10.3389/fvets.2022.839612 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Revealing AIEC Virulence Genes Behind the Mask of Antimicrobial Resistance.
Cell Mol Gastroenterol Hepatol
January 2025
Ruy V. Lourenço Center for Emerging and Re-Emerging Pathogens, Rutgers New Jersey Medical School, Newark, New Jersey; Department of Microbiology, Biochemistry, and Molecular Genetics, Rutgers New Jersey Medical School, Newark, New Jersey. Electronic address:
Meet Our Editorial Board-Genesis. An Interview With Thomas Schimmang, Institute for Biomedicine and Molecular Genetics, Valladolid, Spain.
Genesis
December 2024
Institute for Biomedicine and Molecular Genetics, Unit of Excellence, University of Valladolid and Spanish National Research Council (CSIC), Valladolid, Spain.
Generation and characterization of OX40-ligand fusion protein that agonizes OX40 on T-Lymphocytes.
Front Immunol
January 2025
Laboratory of Molecular Cell Biology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
OX40, a member of the tumor necrosis factor (TNF) receptor superfamily, is expressed on the surface of activated T cells. Upon interaction with its cognate ligand, OX40L, OX40 transmits costimulatory signals to antigen-primed T cells, promoting their activation, differentiation, and survivalprocesses essential for the establishment of adaptive immunity. Although the OX40-OX40L interaction has been extensively studied in the context of disease treatment, developing a substitute for the naturally expressed membrane-bound OX40L, particularly a multimerized OX40L trimers, that effectively regulates OX40-driven T cell responses remains a significant challenge.
View Article and Find Full Text PDFA novel machine learning based framework for developing composite digital biomarkers of disease progression.
Front Digit Health
January 2025
Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ, United States.
Background: Current methods of measuring disease progression of neurodegenerative disorders, including Parkinson's disease (PD), largely rely on composite clinical rating scales, which are prone to subjective biases and lack the sensitivity to detect progression signals in a timely manner. Digital health technology (DHT)-derived measures offer potential solutions to provide objective, precise, and sensitive measures that address these limitations. However, the complexity of DHT datasets and the potential to derive numerous digital features that were not previously possible to measure pose challenges, including in selection of the most important digital features and construction of composite digital biomarkers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!